Processing your payment...
Please do not close your browser.

Tyrosine Kinase JAK Inhibitors Market Growth and Forecast (2022 - 2029) By Type (Tofacitinib, Ruxolitinib, Baricitinib) By Application (Rheumatoid Arthritis (RA), Polycythemia Vera (PCV), Myelofibrosis (MF),) and By Regions

12 Jul, 2022 | 159 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the Tyrosine Kinase JAK Inhibitors Market will register a CAGR of 59 % in terms of revenue and the global market size will reach USD 35 Billion by 2029.

Tyrosine Kinase JAK Inhibitors Market Overview

Tyrosine kinases are molecules that can move the phosphate group from ATP (adenosine triphosphate) to a protein inside of a cell. They serve as a switch that turns various cellular processes on and off. The phosphate group is connected to the amino acid tyrosine on the protein. Tyrosine kinases are a subclass of protein kinases, which link additional amino acids to phosphate groups (threonine and serine). Protein phosphorylation is a crucial technique for linking signals within a cell (signal transduction) and cellular processes including the control of cell division. Kinases carry out this function.

Different tyrosine kinases have a part in the growth of cancer because they are involved in cell migration, proliferation, and survival. Protein kinase mutations can result in unchecked cell proliferation, which can result in the emergence of cancer. As a result, kinase inhibitors like imatinib are successful in treating cancer. The mammalian genome contains about 90 tyrosine kinases, including roughly 30 non-receptors and 60 receptor tyrosine kinases. Receptor tyrosine kinases have extracellular regions used for ligand binding in addition to intracellular domains containing tyrosine kinase enzyme activity and a transmembrane domain.

What is our Tyrosine Kinase JAK Inhibitors Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 59 % during the review period (2022 to 2029).

 

By Type

  • Tofacitinib
  • Ruxolitinib
  • Baricitinib  

 

By Application

 

 

 

 

  • Rheumatoid Arthritis (RA)
  • Polycythemia Vera (PCV)
  • Myelofibrosis (MF)
  • Others

 

 

 

By Companies

  • Pfizer
  • Incyte
  • Novartis
  • Eli Lilly
  • Gilead
  • Sanofi
  • Galapagos
  • AbbVie
  • Vertex
  • Teva
  • Astellas Pharma
  • Celgene
  • CTI BioPharma

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

Base Year

2022

 

Historical Year

 

 

2017 to 2021

Forecast Year

2022 to 2029

Number of Pages

159

Customization Available

Yes, the report can be customized as per your needs

Frequently Asked Questions

What are the current market size and compound annual growth rate (CAGR) of the Tyrosine Kinase JAK Inhibitors Market during the forecast period (2022-2029)?

The Tyrosine Kinase JAK Inhibitors Market is growing at a CAGR of 59 % over the next 7 years.

Who are the key players in Tyrosine Kinase JAK Inhibitors Market?

Pfizer, Incyte, Novartis, Eli Lilly, Gilead, Sanofi, Galapagos, AbbVie, Vertex, Teva, Astellas Pharma, Celgene, CTI BioPharma, and Others.

What region does this Tyrosine Kinase JAK Inhibitors Market report cover?

North America (the United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, Colombia, etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

What is the significant Type of Tyrosine Kinase JAK Inhibitors Market?

Tofacitinib, Ruxolitinib, Baricitinib.

What is the significant Application of the Tyrosine Kinase JAK Inhibitors Market?

Rheumatoid Arthritis (RA), Polycythemia Vera (PCV), Myelofibrosis (MF), Others

Who are the Major Players in Tyrosine Kinase JAK Inhibitors Market?

Market Growth Reports lists out all the Tyrosine Kinase JAK Inhibitors Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Pfizer, Incyte, Novartis, Eli Lilly, Gilead, Sanofi, Galapagos, AbbVie, Vertex, Teva, Astellas Pharma, Celgene, CTI BioPharma, Others

Industry News:

Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

NEW YORK-Pfizer Inc. announced positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherapy trial in the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program (B7451013, or JADE MONO-2). Pfizer announced positive top-line results from the first trial in the JADE program (B7451012, or JADE MONO-1) on May 15, 2019. Complete results from JADE MONO-1 will be presented as a late-breaking abstract at a major upcoming European scientific meeting in Madrid in October 2019.

What are the major Types and Applications for Tyrosine Kinase JAK Inhibitors Market?

By Type, it is segmented into

  • Tofacitinib
  • Ruxolitinib
  • Baricitinib

By Application, it is segmented into

  • Rheumatoid Arthritis (RA)
  • Polycythemia Vera (PCV)
  • Myelofibrosis (MF)
  • Others

Tyrosine Kinase JAK Inhibitors Market Regional Analysis

The market for Janus kinase (JAK) inhibitors is geographically divided into seven regions: Asia Pacific, Europe, Latin America, North America, Oceania, and the Middle East and Africa. Due to rising medical costs and the accessibility of cutting-edge medications, North America is predicted to dominate the market for Janus kinase (JAK) inhibitors.

Another important element that might promote the market's expansion in this area is the general public's growing knowledge of illnesses. For Janus kinase (JAK) inhibitors globally, Europe is anticipated to be the second-largest market.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
  4. Key Insights
    1. Pricing Analysis, By Key Regions, 2022
    2. Price Comparison (USD Per Ton) By Type (Tofacitinib, Ruxolitinib, Baricitinib) 2022
    3. Price Comparison (USD, Per Ton): By Application (Rheumatoid Arthritis (RA), Polycythemia Vera (PCV), Myelofibrosis (MF), Others) 2022
    4. Impact of COVID-19 on the Tyrosine Kinase JAK Inhibitors Market
    5. Production Share of Tyrosine Kinase JAK Inhibitors, By Region, 2022
    6. Key Industry Developments
  5. Global Tyrosine Kinase JAK Inhibitors Market Analysis, Insights and Forecast, 2022-2029
    1. Market Analysis, Insights, and Forecast – By Application
      1. Rheumatoid Arthritis (RA)
      2. Polycythemia Vera (PCV)
      3. Myelofibrosis (MF)
      4. Others 
    2. Market Analysis, Insights, and Forecast – By Type
      1. Tofacitinib
      2. Ruxolitinib
      3. Baricitinib 
    3. Market Analysis, Insights, and Forecast – By Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Rest of World
  6. Competitive Analysis
    1. Global Market Share Analysis (2022)
    2. Company Profiles (Overview, Products, SWOT analysis, recent developments, strategies, financials (based on availability))
      1. Pfizer
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      2. Incyte
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      3. Novartis
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)
      4. Eli Lilly
        1. Overview,
        2. Products,
        3. SWOT analysis,
        4. Recent developments,
        5. strategies,
        6. financials (based on availability)

 

 

 

 

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla